Athens Medical Center

Marousi 15125

1 studies enrolling now · 10 studies all time

What they study most

Anaplastic Lymphoma Kinase-positive, Breast Cancer, Heart Failure, Idiopathic Pulmonary Fibrosis, Locally Advanced or Metastatic Unresectable Urothelial Cancer, Non-small Cell Lung Cancer, Urinary Bladder Neoplasms, Ventricular Tachycardia

Studies at this site

• Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC — Recruiting now
• A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy — Running, not enrolling
• A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder — Running, not enrolling
• Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread — Completed
• Personalized Therapy Study - Attain Stability Quad Post-Approval Study — Running, not enrolling
• Personalized Therapy Study - Intrinsic Antitachycardia Pacing Post-Approval Study (iATP PAS) — Running, not enrolling
• Personalized Therapy Study - HFRS (TriageHF) Post Approval Study — Running, not enrolling
• The OPBC-07/microNAC Study — Running, not enrolling
• A Study to Evaluate Long Term Safety and Efficacy of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis — Stopped early
• A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis — Stopped early